The conference, scheduled for October 8-11, will feature 13 presentations dedicated to EBGLYSS (lebrikizumab-lbkz). These studies provide evidence regarding durable disease control in adolescents and adults, alongside efficacy data for pediatric patients as young as six months. Researchers will also detail the drug's performance in high-impact areas, including the hands and feet.
Beyond atopic dermatitis, the company is introducing research on the intersection of psoriasis and obesity. Six presentations will analyze the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide), utilizing biomarker analysis from the TOGETHER-PsO study to examine potential immunometabolic benefits. Additionally, the company will share long-term outcomes for Olumiant (baricitinib) in pediatric patients with severe alopecia areata, drawing from the BRAVE-AA-PEDS clinical trial.
Comments (0)
No comments yet. Be the first!